Lys-SMCC-DM1

Cat. No.:	HY-101982		
CAS No.:	1281816-04-3		
Molecular Formula:	C ₅₃ H ₇₅ CIN ₆ O ₁₅ S		
Molecular Weight:	1103.71		
Target:	Drug-Linker Conjugates for ADC		
Pathway:	Antibody-drug Conjugate/ADC Related		
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)		

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (90.60 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	0.9060 mL	4.5302 mL	9.0604 mL		
		5 mM	0.1812 mL	0.9060 mL	1.8121 mL		
		10 mM	0.0906 mL	0.4530 mL	0.9060 mL		
	Please refer to the solu	ubility information to select the app	propriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.27 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.27 mM); Clear solution						
	3. Add each solvent o Solubility: ≥ 2.5 mg	ne by one: 10% DMSO >> 90% cor /mL (2.27 mM); Clear solution	n oil				

BIOLOGICAL ACTIVITY				
Description	Lys-SMCC-DM1 (Lys-Nɛ-MCC-DM1) is a <u>agent-linker conjugates for ADC</u> that can inhibit tubulin polymerization. Lys-SMCC- DM1 is the active metabolite of T-DM1. T-DM1 is a HER2-targeting ADC with a tubulin polymerization inhibitor DM1. Lys- SMCC-DM1 can be used in the research of breast cancer ^{[1][2]} .			
IC ₅₀ & Target	Maytansinoids			
In Vitro	Lys-SMCC-DM1 possess a low level of permeability ^[1] . Lys-SMCC-DM1 shows cytotoxicity in KPL-4 and MDA-MB-468 cells, with IC ₅₀ of 24.8 nM and 40.5 nM respectively ^[2] . Lys-SMCC-DM1 (200 μM) inhibits the SLC46A3-mediated uptake of estrone 3-sulfate in MDCKII/SLC46A3 dC cells ^[2] .			

Product Data Sheet



MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tomabechi R, et al. Identification of 5-Carboxyfluorescein as a Probe Substrate of SLC46A3 and Its Application in a Fluorescence-Based In Vitro Assay Evaluating the Interaction with SLC46A3. Mol Pharm. 2022 Dec 2.

[2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA